Distributing opioid overdose reversal medications (2SSB 5195)

Naloxone pilot program

The Naloxone pilot program is a one-time distribution of naloxone to behavioral health agencies (BHAs) in Washington. This pilot is the result of efforts to expand access to opioid reversal medication and listening to feedback from community partners, which showed that BHAs have a high need for upfront funding to purchase the initial stock of naloxone before they can begin a "stock and replenish" model.

Applications will be accepted until August 15.

• Read the naloxone pilot program FAQs
• Naloxone pilot program application form
• Questions about the pilot program can be sent to HCA Naloxone Pilot Program.

Billing resources

• Billing codes and FAQs for Apple Health clients:
  • Go to page 80 under the heading "How do I bill for take-home naloxone" in the prescription drug program billing guide
• Uninsured patients billing information:
  • Billing guide FAQ for uninsured patients
  • Naloxone reimbursement form for uninsured patients
  • Naloxone reimbursement attestation form
  • How to bill for uninsured clients presentation (April 2023)

Education materials

Please reference appendices J and K in the toolkits to locate translated versions of these educational materials.

• Harm reduction strategies and medications for opioid use disorder (MOUD)
• Overdose prevention and direction for naloxone use

Implementation toolkits

Emergency department (ED)

ED toolkit

• SB 5195 Emergency Department implementation toolkit

ED appendices

• Appendix A. SB 5195 ED requirement summary
• Appendix B. Sample naloxone distribution policy
• Appendix C. Sample workflow quick sheet
• Appendix D. Sample smart phrases
• Appendix E. Sample staff training presentation
• Appendix F. Sample staff competency
• Appendix G. Sample distribution signature sheet
• Appendix H. Administrative FAQ
• Appendix I. Clinical staff FAQ
• Appendix J. Opioid overdose prevention and directions for Naloxone use (trifold brochure) (Includes alternate languages)
• Appendix K. Harm reduction strategies and MOUD (trifold brochure) (Includes alternate languages)
• Appendix L. Opioid overdose prevention and directions for Naloxone use (flat sheet)
• Appendix M. Harm reduction strategies and MOUD (flat sheet)

Behavioral health agency (BHA)

BHA toolkit

• SB 5195 Behavioral health agency implementation toolkit

BHA appendices

• Appendix A. SB 5195 BHA requirement quick sheet
• Appendix B. Administrative FAQ
• Appendix C. Frontline staff FAQ
• Appendix D. Sample workflow
• Appendix E. Sample smart phrases
• Appendix F. Sample staff training presentation
• Appendix G. Sample staff competency sheet
• Appendix H. Sample distribution signature sheet
• Appendix I. Opioid overdose prevention and directions for Naloxone use (trifold brochure) (Includes alternate languages)
• Appendix J. Harm reduction strategies and MOUD (trifold brochure) (Includes alternate languages)
• Appendix K. Opioid overdose prevention and directions for Naloxone use (flat sheet)
• Appendix L. Harm reduction strategies and MOUD (flat sheet)

Technical assistance

• HCA Lunch and Learn series for behavioral health agencies (December 8, 2022)
  • Watch the webinar
  • View the slide deck
• HCA Lunch and Learn series for behavioral health agencies (December 15, 2022)
  • Watch the webinar
  • View the slide deck
• Report to the Legislature on opioid overdose reversal medication bulk purchasing and distribution program